Gail B Cross, Intan P Sari, Cissy Kityo, Qingshu Lu, Yogesh Pokharkar, Rajesh B Moorakonda, Han-Nguyen Thi, Quyet Do, Victoria B Dalay, Emmanuel Gutierrez, Vincent M Balanag, Randy J Castillo, Henry Mugerwa, Felic Fanusi, Philip Kwan, Ka Lip Chew, Nicholas I Paton
BACKGROUND: Shorter treatments are needed for drug-susceptible tuberculosis. Adjunctive statins increase bactericidal activity in preclinical tuberculosis models. We investigated the safety and efficacy of adjunctive rosuvastatin in people with tuberculosis. We tested the hypothesis that adjunctive rosuvastatin accelerates sputum culture conversion within the first 8 weeks of treatment of rifampicin-susceptible tuberculosis. METHODS: This phase 2b, randomised, open-label, multicentre trial conducted in five hospitals or clinics in three countries with high tuberculosis burden (ie, the Philippines, Viet Nam, and Uganda) enrolled adult participants aged 18-75 years with sputum smear or Xpert MTB/RIF positive, rifampicin-susceptible tuberculosis who had received less than 7 days of previous tuberculosis treatment...
March 23, 2023: Lancet Infectious Diseases